Subscribe To
Immupharma plc partner makes final preparations for phase iii trial
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said its US partner has sought final regulatory guidance from the Food & Drug Administration as it ‘actively pre...
June 27, 2022, 3:12 am
Rigel (rigl) waiha study fails to meet goals, stock tanks
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia ...
June 9, 2022, 2:17 pm
Immunic, inc. to participate in scientific, industry and investor conferences in june
NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...
June 8, 2022, 6:30 am
Immunovant to report fourth quarter and full year 2022 financial results on june 8, 2022
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal liv...
June 6, 2022, 4:47 pm
Argenx to present at upcoming investor conferences
June 1 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suff...
June 1, 2022, 1:00 am
Brickell biotech to report first quarter 2022 financial results and provide a corporate update on may 12, 2022
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmace...
May 5, 2022, 4:01 pm
Argenx to present at bofa securities 2022 healthcare conference
May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffe...
May 4, 2022, 1:00 am
Alpine immune sciences announces participation in may investor conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...
May 3, 2022, 8:05 am
Argenx to report first quarter 2022 financial results and business update on may 5, 2022
April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suf...
April 28, 2022, 1:00 am
Argenx (argx) up on positive autoimmune disorder study data
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravi...
March 23, 2022, 9:47 am
Argenx's subcutaneous efgartigimod at par with intravenous administration in neuromuscular disorder
Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized mya...
March 22, 2022, 12:30 pm
Shattuck labs to present two posters at the 2022 american association for cancer research (aacr) annual meeting
AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology compa...
March 9, 2022, 8:21 am
Xencor to present preclinical data from xmab® cytokine programs at the american association for cancer research (aacr) annual meeting 2022
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki...
March 8, 2022, 4:31 pm
Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...
March 7, 2022, 12:06 pm
Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...
March 7, 2022, 12:06 pm
Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...
March 7, 2022, 12:06 pm
Ventyx biosciences to participate in the barclays global healthcare conference
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...
March 7, 2022, 8:00 am
Ventyx biosciences to participate in the barclays global healthcare conference
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...
March 7, 2022, 8:00 am
Ventyx biosciences to participate in the barclays global healthcare conference
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...
March 7, 2022, 8:00 am
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm